AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Feb 28, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2006.107367v1
97/4/589-a    most recent
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Green, N. S.
Right arrow Articles by Murray, T. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Green, N. S.
Right arrow Articles by Murray, T. H.
Related Collections
Right arrow Genetics
April 2007, Vol 97, No. 4 | American Journal of Public Health 589-590
© 2007 American Public Health Association
DOI: 10.2105/AJPH.2006.107367

LETTER

GREEN AND MURRAY RESPOND

Nancy S. Green, MD and Thomas H. Murray, PhD

Nancy S. Green is with the March of Dimes, White Plains, NY. Thomas H. Murray is with the Hastings Center, Garrison, NY.

Correspondence: Requests for reprints should be sent to Nancy S. Green, MD, Medical Director, March of Dimes, 1275 Mamaroneck Ave, White Plains, NY 10605 (e-mail: ngreen@modimes.org).

Because this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

We thank Ross for suggesting a potential improvement in newborn screening (NBS) for cystic fibrosis (CF) by adding a second-tier enzyme-linked immunosorbent assay for pancreatic-associated protein for those samples screening positive by immunoreactive trypsinogen (IRT).1 The addition of pancreatic-associated protein may improve the specificity of screening, perhaps bypassing some of the difficulties that we note with secondary DNA-based CF screening as it is currently practiced.2 However, the limitations of DNA-based screening by assay of only a minority of the known mutations in the CF gene can be better addressed by increasing the number of mutations analyzed. Accurate genotyping will be . . . [Full Text]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Public Health Association